Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis

Changhai Hospital80 enrolled

Overview

This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT in patients with moderate to severe acute pancreatitis.

This study is a single center, randomized controlled trial. After the start of the study, 80 patients with acute moderate to severe acute pancreatitis were randomly selected according to inclusion and exclusion criteria and divided into an intervention group (n=40) and a control group (n=40) to explore the safety and efficacy of FMT in preventing late complications of acute moderate to severe acute pancreatitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Acute Pancreatitis Severe Acute Pancreatitis

Interventions

FMTPROCEDURE

FMT bacterial solution will be injected through a nasojejunal nutrition tube once a day for five days.

PlaceboPROCEDURE

Physiological saline placebo will be injected through a nasojejunal nutrition tube once a day for five days.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: Age: 18-70 years old Diagnosis: Meets the diagnostic criteria for severe acute pancreatitis (SAP) * Organ function: There may be organ failure and systemic complications that can be recovered within 48 hours * Stage of the disease: Approximately 2 weeks after onset (non acute phase), accompanied by accumulation of pancreatic fluid volume, and significant improvement in CTSI score compared to before (grade II) * Nutritional support: Enteral nutrition tube has been left in place Feasibility of transplantation: No absolute contraindications for gut microbiota transplantation * Informed Consent: Voluntarily sign a written informed consent form * Gastrointestinal status: Abdominal pressure (bladder pressure measurement)\<12mmHg ◦ Existence of spontaneous defecation/exhaust Significant improvement in abdominal distension compared to before Exclusion Criteria: Serious complications: combined gastrointestinal bleeding or intestinal fistula * Special population: Pregnant or lactating women * Informed refusal: Failure to sign informed consent form * Basic organ dysfunction: Prior to admission, there were chronic organ dysfunction in the heart, lungs, liver, kidneys, or blood system Malignant tumor: Suffering from incurable malignant tumors * Immune abnormalities: Autoimmune diseases ◦ Immunosuppression status (solid organ/bone marrow transplantation history, AIDS, long-term use of immunosuppressants/hormones) * Enteral nutrition intolerance: unable to meet 50% of calorie requirements due to severe diarrhea, fibrotic intestinal stenosis, severe gastrointestinal edema, high flow intestinal fistula, etc * Systemic infection: meets the diagnostic criteria for systemic inflammatory response syndrome (SIRS) * Antibiotic dependence: broad-spectrum antibiotic intervention is required for combined extraintestinal organ infections * Immunodeficiency: Congenital or acquired immunodeficiency * Mental illness: severe mental disorders

Locations (2)

Changhai Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Changhai Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Pancreatic infectious complications

Infectious pancreatic necrosis, sepsis, and pancreatic fistula. Infectious pancreatic necrosis: (1) Imaging suggests the formation of gas at the site of necrosis aggregation; (2) Gram staining or culture positivity of necrotic specimens obtained through percutaneous fine needle aspiration (FNAC); (3) Clinically suspected infection symptoms. However, due to the high false positive rate, routine FNAC examination is not recommended. Sepsis: (1) Two blood cultures (or bone marrow cultures) are positive for the same pathogen. (2) Systemic inflammatory response syndrome (SIRS) occurs. Pancreatic fistula: (1) History of acute necrotizing pancreatitis attacks; (2) Imaging supports the diagnosis of pancreatic fistula. Measurement: Yes/No (incidence rate)

Time frame: through study completion, an average of 1 year

Secondary Outcomes

Change in CTSI score

The CT Severity Score (CTSI) of acute pancreatitis can evaluate the severity of acute pancreatitis, predict the probability of complications such as organ failure in the early stages of the disease, and assess the prognosis of patients Method: Measure CTSI scores during baseline and after FMT treatment

Time frame: through study completion, an average of 1 year

Changes in gut microbiome community

The average change in bacterial species relative to baseline compared to one week after fecal microbiota transplantation (FMT).

Time frame: Up to 1 week

Gastrointestinal mucosal barrier index

Diamine oxidase (DAO): It is a marker enzyme of intestinal mucosal cells. D-Lactic acid: It is a metabolic product of intestinal bacteria. Under normal circumstances, the content in plasma is extremely low. When the intestinal mucosa is damaged, DAO and D-lactate will be released into the blood in large quantities, leading to a significant increase in blood concentration, which is an important indicator for evaluating the structural integrity of the intestinal mucosa. During the treatment process, changes in DAO and D-lactate levels can reflect the progress of intestinal mucosal repair. DAO decline rate Formula: (Baseline Value -7-Day Value)/Baseline Value x 100% Unit:% D-lactic acid decline rate Formula: (Baseline Value -7-Day Value)/Baseline Value x 100% Unit:%

Central Contacts

Kong Xiang yu, associate professor

CONTACT

13564644397 xiangyukong185@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.